扩展基因组测序联合听力筛查与新生儿重症监护病房新生儿听力损失检出之间的关联
这项队列研究于2016年8月8日至2020年12月31日在上海复旦大学附属儿科医院NICU纳入8078名新生儿,每名患儿接受听力筛查和覆盖2742个基因的扩展基因组测序,筛查未通过或基因结果阳性者在中位3月龄时转诊诊断性听力学检查。240名转诊患儿中52名(21.7%)诊断为听力损失,联合策略使听力筛查漏诊的听力损失诊断增加15.6%(7/45)。52名听力损失患儿中39名(75.0%)检出遗传因素,GJB2和SLC26A4最常见;有遗传发现者听力损失程度更重(极重度21、重度4、中度7、轻度7 vs 重度2、中度4、轻度7;P=0.005),双侧听力损失更多(39/39[100%] vs 9/13[69.2%];P=0.003)。作者认为扩展基因组测序联合听力筛查可能有效检出NICU患儿的听力损失。
要点
- 8078名NICU新生儿接受听力筛查联合覆盖2742个基因的扩展基因组测序,筛查未通过或基因阳性者中位3月龄转诊诊断性听力学检查。
- 240名转诊患儿中52名(21.7%)诊断听力损失,联合策略使听力筛查漏诊的听力损失诊断增加15.6%(7/45)。
- 52名听力损失患儿中39名(75.0%)检出遗传因素,GJB2和SLC26A4为最常见基因。
- 有遗传发现者听力损失更重(极重度21、重度4、中度7、轻度7 vs 重度2、中度4、轻度7;P=0.005),双侧比例更高(39/39[100%] vs 9/13[69.2%];P=0.003)。
- 作者认为扩展基因组测序联合听力筛查可能有效检出NICU患儿的听力损失。
适用人群与场景
- 2016年8月8日至2020年12月31日入住上海复旦大学附属儿科医院NICU的8078名新生儿(男孩4666名[57.8%];中位日龄6.3天[IQR 3.0-12.0天])。
- 2021年9月1日至11月30日通过电话访谈随访听力状态。
处置流程与药物剂量
- 每名患儿接受听力筛查和覆盖2742个基因的扩展基因组测序。
- 听力筛查未通过或基因结果阳性者在中位3月龄时转诊诊断性听力学检查。
研究设计与关键结果
- 队列研究:8078名NICU新生儿,每名接受听力筛查和覆盖2742个基因的扩展基因组测序,筛查未通过或基因阳性者中位3月龄转诊诊断性听力学检查。
- 240名转诊患儿中52名(21.7%)诊断为听力损失。
- 扩展基因组测序联合听力筛查使听力筛查漏诊的听力损失诊断增加15.6%(7/45)。
- 52名听力损失患儿中39名(75.0%)检出遗传因素,GJB2和SLC26A4为最常见基因。
- 有遗传发现者听力损失程度更重:极重度21、重度4、中度7、轻度7 vs 无遗传发现者重度2、中度4、轻度7(P=0.005)。
- 有遗传发现者双侧听力损失更多:39/39(100%)vs 9/13(69.2%)(P=0.003)。
- 接受基因组测序联合听力筛查的患者临床管理策略发生改变。
证据类型、等级与局限
- 研究类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,扩展基因组测序联合听力筛查可能有效检出NICU患儿的听力损失。
- 原文报告接受基因组测序联合听力筛查的患者临床管理策略发生改变。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Hearing loss is a global social burden. Early identification of hearing loss missed by newborn hearing screening tests in the neonatal intensive care unit is crucial.
OBJECTIVE: To assess the association between expanded genomic sequencing combined with hearing screening and detection of hearing loss as well as improvement in the neonatal intensive care unit.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was performed between August 8, 2016, and December 31, 2020, among 8078 newborns admitted to the neonatal intensive care unit of the Children's Hospital of Fudan University in Shanghai, China. Follow-up for hearing status was performed via telephone interviews between September 1 and November 30, 2021.
EXPOSURES: A hearing screening test and the expanded genomic sequencing targeting 2742 genes were administered to each patient. Those who failed the hearing screening test or had positive genetic findings were referred for diagnostic audiometry at a median of 3 months of age.
MAIN OUTCOMES AND MEASURES: The primary outcome was hearing loss missed by hearing screening test. Secondary outcomes were genetic findings and benefits associated with the expanded genomic sequencing for clinical management of patients in the neonatal intensive care unit.
RESULTS: Of 8078 patients (4666 boys [57.8%]; median age, 6.3 days [IQR, 3.0-12.0 days]), 52 of 240 (21.7%) received a diagnosis of hearing loss. Expanded genomic sequencing combined with hearing screening was associated with a 15.6% increase (7 of 45 patients) in cases of diagnosed hearing loss that were missed by hearing screening. Of the 52 patients with hearing loss, genetic factors were identified for 39 patients (75.0%); GJB2 and SLC26A4 were the most common genes identified. Patients with genetic findings experienced a more severe degree of hearing loss than those without genetic findings (21 profound, 4 severe, 7 moderate, and 7 mild vs 2 severe, 4 moderate, and 7 mild; P = .005), with more bilateral hearing loss (39 of 39 [100%] vs 9 of 13 [69.2%]; P = .003). Clinical management strategies were changed for patients who underwent genomic sequencing combined with hearing screening.
CONCLUSIONS AND RELEVANCE: This study suggests that expanded genomic sequencing combined with hearing screening may be effective at detecting hearing loss among patients in the neonatal intensive care unit.
参考来源
- Zhu Y, Hu L, Yang L, et al. Association Between Expanded Genomic Sequencing Combined With Hearing Screening and Detection of Hearing Loss Among Newborns in a Neonatal Intensive Care Unit. JAMA Netw Open. 2022. PMID: 35816303. doi:10.1001/jamanetworkopen.2022.20986
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。